ISRCTN ISRCTN16425757
DOI https://doi.org/10.1186/ISRCTN16425757
Clinical Trials Information System (CTIS) 2026-525575-22-00
Integrated Research Application System (IRAS) 1014010
Central Portfolio Management System (CPMS) 76628
Sponsor code KLR003-Clin-004
Sponsor Klear Bio, Inc.
Funder Klear Bio, Inc.
Submission date
24/09/2026
Registration date
01/10/2026
Last edited
06/11/2026
Recruitment status
Recruiting
Overall study status
Deferred
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Contact information

Timothy P Reilly
Public

Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
MA 02139
United States of America

Phone +1 (617) 256-2763
Email clinicaltrials@klear.bio
Timothy P Reilly
Scientific

Klear Bio, Inc.
300 Technology Square, 8th Floor
Cambridge
MA 02139
United States of America

Phone +1 (617) 256-2763
Email Tim@klear.bio
Hamish Hunter
Principal investigator

Medicines Evaluation Unit (MEU) Ltd
The Langley Building
Southmoor Road
Manchester
M23 9QZ6
United Kingdom

Phone +44 0161 946 4071
Email hhunter@meu.org.uk

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingBlinded (masking used)
ControlPlacebo
AssignmentThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
PurposeTreatment
Scientific titleDeferred registration - Klear Bio Code: KLR003-Clin-004 [Full scientific title to be added on or before the deferral expiry date]
Study objectives The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Ethics approval(s)

Approved 10/09/2026, North East - York Research Ethics Committee (Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; york.rec@hra.nhs.uk), ref: 26/NE/0079

Health condition(s) or problem(s) studiedThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
InterventionThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Intervention typeDrug
PhasePhase I
Drug / device / biological / vaccine name(s)The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Primary outcome measure(s)
  1. The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date measured using [Metric or method of measurement] at [Timepoint(s)]
Key secondary outcome measure(s)
Completion date30/10/2028

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit65 Years
SexAll
Target sample size at registration183
Key inclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Key exclusion criteriaThe Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
Date of first enrolment13/05/2026
Date of final enrolment05/06/2028

Locations

Countries of recruitment

  • United Kingdom
  • England
  • Netherlands
  • United States of America

Study participating centre

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date
-
-
England

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

06/11/2026: Internal review.
25/09/2026: Study's existence confirmed by the Health Research Authority (HRA) (UK).